Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.763 | 0.360 | 3 | 122120794 | 3 prime UTR variant | G/A;C | snv |
|
Infections | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||||
|
0.925 | 0.120 | 3 | 122098766 | intron variant | G/A | snv | 0.26 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.925 | 0.120 | 3 | 122098766 | intron variant | G/A | snv | 0.26 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.925 | 0.080 | 3 | 122119944 | 3 prime UTR variant | T/C | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.020 | 1.000 | 2 | 2015 | 2018 | ||||||||
|
0.925 | 0.080 | 3 | 122119944 | 3 prime UTR variant | T/C | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.020 | 1.000 | 2 | 2015 | 2018 | ||||||||
|
0.763 | 0.360 | 3 | 122120794 | 3 prime UTR variant | G/A;C | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.763 | 0.360 | 3 | 122120794 | 3 prime UTR variant | G/A;C | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.925 | 0.080 | 3 | 122102296 | intron variant | T/A;G | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.925 | 0.080 | 3 | 122102296 | intron variant | T/A;G | snv |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.882 | 0.120 | 3 | 122081640 | intron variant | A/C | snv | 0.31 |
|
Immune System Diseases; Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.882 | 0.120 | 3 | 122081640 | intron variant | A/C | snv | 0.31 |
|
0.700 | 1.000 | 1 | 2016 | 2016 | ||||||||
|
0.724 | 0.400 | 3 | 122119472 | missense variant | G/A | snv | 0.30 | 0.25 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
|
0.724 | 0.400 | 3 | 122119472 | missense variant | G/A | snv | 0.30 | 0.25 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
|
0.724 | 0.400 | 3 | 122119472 | missense variant | G/A | snv | 0.30 | 0.25 |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.020 | 0.500 | 2 | 2018 | 2019 | ||||||
|
0.724 | 0.400 | 3 | 122119472 | missense variant | G/A | snv | 0.30 | 0.25 |
|
Pathological Conditions, Signs and Symptoms; Infections | 0.020 | 0.500 | 2 | 2018 | 2019 | ||||||
|
0.724 | 0.400 | 3 | 122119472 | missense variant | G/A | snv | 0.30 | 0.25 |
|
Immune System Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
|
3 | 122062876 | intron variant | T/C | snv | 0.19 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
0.882 | 0.120 | 3 | 122081640 | intron variant | A/C | snv | 0.31 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2020 | 2020 |